Jpmorgan Chase & CO Regulus Therapeutics Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 78,972 shares of RGLS stock, worth $129,514. This represents 0.0% of its overall portfolio holdings.
Number of Shares
78,972
Previous 26,913
193.43%
Holding current value
$129,514
Previous $48,000
156.25%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding RGLS
# of Institutions
74Shares Held
56.5MCall Options Held
79.3KPut Options Held
20.3K-
Federated Hermes, Inc. Pittsburgh, PA12.9MShares$21.1 Million0.05% of portfolio
-
Nea Management Company, LLC Timonium, MD6.47MShares$10.6 Million0.78% of portfolio
-
Vivo Capital, LLC Palo Alto, CA5MShares$8.2 Million1.15% of portfolio
-
Octagon Capital Advisors LP New York, NY4.26MShares$6.99 Million1.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.09MShares$6.71 Million0.0% of portfolio
About Regulus Therapeutics Inc.
- Ticker RGLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,634,400
- Market Cap $24M
- Description
- Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...